



Shen-yi Li En-yu Wang

Endometrial Carcinoma

With the Collaboration of Michihiro Seta

With 67 Figures and 57 Tables

The People's Medical Publishing House Beijing

Springer-Verlag Berlin Heidelberg New York
London Paris Tokyo Hong Kong Barcelona

Authors and Translators

Dr. Shen-yi Li

Associate Professor, Gynecologic Oncology Department
Chief of Medical Affairs Branch

Dr. En-yu Wang

Associate Professor, Gynecologic Oncology Department

Cancer Institute (Hospital)

Chinese Academy of Medical Sciences

Beijing 100021, P.R.China

Original Chinese Edition published by
The People's Medical Publishing House, Beijing, 1988

ISBN-13: 978-3-540-51273-8

e-ISBN-13: 978-3-642-74821-9

DOI: 10.1007/978-3-642-74821-9

Library of Congress Cataloging-in-Publication Data.

Li, Shen-yi, 1941-

Endometrial carcinoma/Shen-yi Li, En-yu Wang; contributor, Michihiro Seta.
p.cm.

Translation of an original Chinese ed. published by the People's Medical
Pub. House, Beijing, 1988.

Includes bibliographical references.

ISBN 0-387-51273-X (U.S.: alk. paper)

1. Endometrium-Cancer. I. Wang, En-yu, 1942- II. Seta, Michihiro. III. Title.
[DNLM: 1. Uterine Neoplasms. WP 460 L693e]

RC280.U8L47 1990 616.99'466-dc20 DNLM/DLC 90-9694

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in other ways, and storage in data banks. Duplication of this publication or parts thereof is only permitted under the provisions of the German Copyright Law of September 9, 1965, in its current version, and a copyright fee must always be paid. Violations fall under the prosecution act of the German Copyright Law.

© The People's Medical Publishing House Beijing and Springer-Verlag Berlin Heidelberg 1990

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Product Liability: The publisher can give no guarantee for information about drug dosage and application thereof contained in the book. In every individual case the respective user must check its accuracy by consulting other pharmaceutical literature.

*Dedicated in Gratitude
to Our Teachers*

Preface

During the past 20 years, endometrial carcinoma has continued to increase in frequency and it is quite possible that this carcinoma will become the major gynecologic malignancy in the future. For many years, endometrial carcinoma was considered less malignant than other gynecologic malignancies, simple hysterectomy and bilateral salpingo-oophorectomy or surgery combined with radiation being effective in certain circumstances. It is unfortunate to note that the global 5-year survival rate for patients with advanced or recurrent endometrial carcinoma has improved only slightly. Therefore any complacency regarding this 'benign malignancy' should be reconsidered.

There is a growing awareness of the nature of endometrial carcinoma, with advances in our knowledge ranging from its etiology through its epidemiology to its clinical findings. This volume has been designed to fill a hiatus in the literature in China. To achieve this aim, we have attempted to review the world-wide advances on endometrial carcinoma and summarize systematically and comprehensively this common gynecologic malignancy, including the clinical experiences gathered at the Cancer Institute (Hospital) of the Chinese Academy of Medical Sciences since 1958 as well as a brief description of the psychological problems in patients with gynecologic cancers.

We are very grateful to our photographer, Mr. Liu Xi-Chan for the high quality of the photographs. We would also like to express our sincere thanks to the publishers for their care and efficiency in preparing the text and illustrations, and particularly to Dr. Ute Heilmann, who edited the text with much patience and genuine understanding.

Beijing, March 1990

Shen-yi Li
En-yu Wang

Contents

1	Epidemiology and Etiology	1
1.1	Epidemiology.....	1
1.2	Etiology.....	5
1.2.1	Age.....	5
1.2.2	Obesity.....	5
1.2.3	Nulliparity.....	6
1.2.4	Late Menopause.....	7
1.2.5	Diabetes Mellitus, Hypertension, and Associated Internal Medical Diseases.....	7
1.2.6	Ovarian Tumors and Ovarian Diseases....	8
1.2.7	Oral Contraceptives.....	8
1.2.8	Exogenous Estrogen.....	8
1.2.9	Previous Pelvic Irradiation.....	9
1.2.10	Summary.....	10
	References.....	17
2	Pathology	23
2.1	Pathologic Manifestation of Endometrial Carcinoma.....	23
2.1.1	Gross Characteristics.....	23
2.1.2	Microscopic Appearances.....	25
2.1.3	Histologic Grade.....	32
2.1.4	Pattern of Spread.....	34
2.2	Ultrastructural, Chromosomal Karyotyping, and Nuclear DNA Studies .	37
2.2.1	Ultrastructural Studies.....	37
2.2.2	Chromosomal Karyotyping and Nuclear DNA Studies.....	40
2.3	Rare Types of Endometrial Carcinoma . . .	41
2.3.1	Argyrophil Cell Carcinoma of Small Cell Carcinoma.....	41

X Contents

2.3.2 Primary Pure Squamous Cell Carcinoma of the Endometrium. 43

2.4 Endometrial Hyperplasia and Adenocarcinoma in Situ 44

2.4.1 Classification of Endometrial Hyperplasia. 44

2.4.2 Pathology of Endometrial Hyperplasia . . . 46

2.4.3 Relationships of Various Forms of Endometrial Hyperplasia. 49

2.4.4 Etiology and Pathogenesis of Endometrial Hyperplasia 50

2.4.5 Carcinoma in Situ of the Endometrium. . . 50

2.4.6 Distinction Between Hyperplasia and Adenocarcinoma 52

References 54

3 Diagnosis of Endometrial Carcinoma 59

3.1 Clinical Manifestation 59

3.1.1 Age 59

3.1.2 Symptoms 59

3.1.3 Pelvic Examination 60

3.2 Diagnosis. 60

3.2.1 Endometrial Sampling of the Uterine Cavity 60

3.2.2 Cytologic Examination 62

3.2.3 Hysteroscopy 63

3.2.4 Computerized Tomography. 69

3.2.5 Magnetic Resonance Imaging 72

3.2.6 Ultrasonographic Assessment of Endometrial Carcinoma 75

3.2.7 Pelvic Lymphography 75

3.3 Differential Diagnosis 77

3.3.1 Differential Diagnosis of Endometrial Carcinoma 77

3.3.2 Association of Endometrial Carcinoma with Other Malignancies or Pregnancy . . . 77

3.3.3 Rare Cases of Endometrial Carcinoma . . . 82

3.4 Clinical Staging 84

References 87

4	Treatment of Endometrial Carcinoma	93
4.1	Historical Review.	93
4.2	Surgical Treatment	97
4.2.1	Value of Surgical Treatment	97
4.2.2	Common Surgical Approaches for Endometrial Carcinoma.	99
4.2.3	Problems of Surgery	115
4.3	Radiotherapy.	118
4.3.1	Indication and Value	118
4.3.2	Intracavitary Irradiation	119
4.3.3	External Beam Therapy.	128
4.4	Hormonal Treatment.	131
4.4.1	Progestogens	131
4.4.2	Antiestrogens.	138
4.4.3	Combination of Progestogens with Antiestrogens.	140
4.4.4	Use of Estrogen After Surgery and Irradiation for Endometrial Carcinoma. . .	142
4.5	Chemotherapy.	142
4.5.1	Single-Agent Chemotherapy.	143
4.5.2	Combination Chemotherapy	144
4.6	Suggested Therapy in Each Stage of Endometrial Carcinoma.	145
4.6.1	Stage I	145
4.6.2	Stage II	146
4.6.3	Stages III and IV.	146
4.6.4	Recurrent Disease	147
	References	150
5	Prognosis of Endometrial Carcinoma	159
5.1	Treatment Result.	159
5.2	Recurrence.	159
5.2.1	Recurrence Rate.	159
5.2.2	Interval Between Primary Treatment and Recurrence.	159
5.2.3	Recurrence Location	160
5.2.4	Treatment and Prognosis of Recurrence .	161

XII Contents

5.3	Prognostic Factors	161
5.3.1	Age	161
5.3.2	Clinical Stages	162
5.3.3	Lymph Node Involvement.	163
5.3.4	Myometrial Invasion	164
5.3.5	Cervical Involvement	169
5.3.6	Uterine Size	170
5.3.7	Histologic Differentiation.	171
5.3.8	Histologic Type	172
5.3.9	Tumor Volume	173
5.3.10	Distance of the Lesion from the Internal Cervical Os	173
5.3.11	Pathology of Pericancerous Endometrium	176
5.3.12	Peritoneal Cytology.	176
5.3.13	Hormone Receptor	177
5.3.14	Treatment Modalities	178
	References	180
6	Laboratory Research	185
6.1	Steroid Hormone Receptors of Endometrial Carcinoma	185
6.1.1	Discovery of Sex Steroid Hormone Receptors.	186
6.1.2	Definition and Characteristics of Steroid Hormone Receptors.	187
6.1.3	Intracellular Mechanism of Action of Steroid Receptors.	188
6.1.4	Methodology of Steroid Hormone Receptor Detection	191
6.1.5	Physiology of Steroid Receptors in Normal Tissues	203
6.1.6	Estrogen Receptors and Progesterone Receptors in Endometrial Carcinoma	205
6.1.7	Estrogen Receptors and Progesterone Receptors in Ovarian Carcinoma and Cervical Carcinoma	206
6.2	Monoclonal Antibody in Cancer	210
6.2.1	Basic Principles	210
6.2.2	Procedures for Generating Monoclonal Antibodies	212

6.2.3	Application of Monoclonal Antibodies . .	212
	References	219
7	Medicopsychologic Problems in Patients with Gynecologic Cancers	226
7.1	Psychologic Problems in Patients with Gynecologic Cancers	226
7.1.1	Concept of Psychologic Stress	226
7.1.2	Psychologic Stress in Each Stage of Medical Course	227
7.1.3	Psychologic Components in Patients with Gynecologic Cancers	228
7.2	Medical Intervention and Nursing Care of Patients with Gynecologic Cancers	233
7.2.1	Psychophysiologic Care	233
7.2.2	Physical Care	236
7.2.3	Social Care	237
7.3	Euthanasia	238
7.3.1	Basic Concepts	238
7.3.2	Quality of Life, Human Suffering, and Euthanasia	239
	References	240